1.Yang CR, Svensson KA. Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008;120:317–332.
2.Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010;47:4–16.
3.Hons J, Zirko R, Ulrychova M, Cermakova E, Doubek P, Libiger J. Glycine serum level in schizophrenia: relation to negative symptoms. Psychiatry Res 2010;176:103–108.
4.Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative symptoms of schizophrenia. Psychopharmacology (Berl) 2008;200:217–230.
5.Kanahara N, Shimizu E, Ohgake Set al. Glycine and d-serine, but not d-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) 2008;198:363–374.
6.Allen NC, Bagade S, McQueen MBet al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008;40:827–834.
7.Talbot K, Eidem WL, Tinsley CLet al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004;113:1353–1363.
8.Weickert CS, Straub RE, McClintock BWet al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004;61:544–555.
9.Hashimoto R, Noguchi H, Hori Het al. A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. World J Biol Psychiatry 2010;11:431–438.
10.Hashimoto R, Noguchi H, Hori Het al. Association between the dysbindin gene (DTNBP1) and cognitive functions in Japanese subjects. Psychiatry Clin Neurosci 2009;63:550–556.
11.Olgiati P, Mandelli L, Lorenzi Cet al. Schizophrenia: genetics, prevention and rehabilitation. Acta Neuropsychiatr 2009;21:109–120.
12.Hattori S, Murotani T, Matsuzaki Set al. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 2008;373:298–302.
13.Takao K, Toyama K, Nakanishi Ket al. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol Brain 2008;1. doi:10.1186/1756-6606-1-11.
14.Nihonmatsu-Kikuchi N, Hashimoto R, Hattori Set al. Reduced rate of neural differentiation in the dentate gyrus of adult dysbindin null (sandy) mouse. PLoS One 2011;6:e15886.
15.Kobayashi K, Umeda-Yano S, Yamamori H, Takeda M, Suzuki H, Hashimoto R. Correlated alterations in serotonergic and dopaminergic modulations at the hippocampal mossy fiber synapse in mice lacking dysbindin. PLoS One 2011;6:e18113.
16.Nagai T, Kitahara Y, Shiraki Aet al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: an in vivo microdialysis study. Neurosci Lett 2010;470:134–138.
17.Numakawa T, Yagasaki Y, Ishimoto Tet al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699–2708.
18.Kishimoto M, Ujike H, Motohashi Yet al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 2008;63:191–196.
19.Abekawa T, Ito K, Nakagawa S, Nakato Y, Koyama T. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr Res 2008;101:84–94.
20.Ito K, Abekawa T, Koyama T. Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine. Psychopharmacology (Berl) 2006;187:293–302.
21.Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. San Diego: Academic Press, 2001.
22.Abekawa T, Ito K, Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2006;374:177–193.
23.Chefer VI, Shippenberg TS. Paradoxical effects of prodynorphin gene deletion on basal and cocaine-evoked dopaminergic neurotransmission in the nucleus accumbens. Eur J Neurosci 2006;23:229–238.
24.Feng YQ, Zhou ZY, He Xet al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res 2008;106:218–228.
25.Hikita T, Taya S, Fujino Yet al. Proteomic analysis reveals novel binding partners of dysbindin, a schizophrenia-related protein. J Neurochem 2009;110:1567–1574.
26.Legendre P. The glycinergic inhibitory synapse. Cell Mol Life Sci 2001;58:760–793.
27.Perry KW, Falcone JF, Fell MJet al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008;55:743–754.
28.Labrie V, Clapcote SJ, Roder JC. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol Biochem Behav 2009;91:610–620.
29.Shimazaki T, Kaku A, Chaki S. d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010;209:263–270.
30.Gaspar PA, Bustamante ML, Silva H, Aboitiz F. Molecular mechanisms underling glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem 2009;111:891–900.
31.Abekawa T, Ohmori T, Koyama T. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res 1994;643:276–281.
32.Karlsgodt KH, Robleto K, Trantham-Davidson Het al. Reduced dysbindin expression mediates N-methyl-d-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 2011;69:28–34.
33.Dyck B, Guest K, Sookram C, Basu D, Johnson R, Mishra RK. PAOPA, a potent analogue of Pro–Leu–glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophr Res 2011;125:88–92.
34.Karlsson RM, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2009;34:1578–1589.
35.Nestler EJ, Hyman SE, Malenka RC, eds. Molecular neuropharmacology: a foundation for clinical neuroscience. New York: McGraw Hill, 2001.